Humacyte, Inc. (HUMA) vs NovaBridge Biosciences (NBP)
Humacyte, Inc. and NovaBridge Biosciences are both Biotechnology companies. Humacyte, Inc. and NovaBridge Biosciences are of similar size ($172.8M and $166.7M). Humacyte, Inc. grew revenue faster over the last twelve months: 149.8% against −91.8%. NovaBridge Biosciences has the higher net margin (0.00% vs −4,448.9%) and the higher return on invested capital (0.00% vs −433.7%). Across the 17 metrics below, NovaBridge Biosciences leads on 13 and Humacyte, Inc. on 4.
Valuation
Profitability
| Metric | HUMA | NBP | Biotechnology median |
|---|---|---|---|
| Gross margin | (494.58%) | 31.10% | 65.16% |
| Operating margin | (5,240.78%) | 0.00% | 0.00% |
| Net margin | (4,448.89%) | 0.00% | 0.00% |
| Free cash flow margin | (4,599.72%) | 0.00% | 0.00% |
| Return on equity | (534.42%) | 0.00% | (57.72%) |
| Return on assets | (68.16%) | 0.00% | (49.22%) |
| Return on invested capital | (433.66%) | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack